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Copy number variants (CNVs) play a significant role in the etiology of Autism Spectrum 
Disorders (ASDs). Recurrent CNV risk variants are found in about 10-15% of patients with ASD 
and intellectual disability (ID). Moreover, the contribution of de novo CNVs is evidenced by 
unique causal CNVs in syndromic ASD and by the overrepresentation of de novo CNVs in ASD 
patients versus unaffected siblings in large scale studies. However little is known on the precise 
contribution of CNVs in patients with non-syndromic ASD. 
 
In the current study deletions, duplications and multiplications are studied in relation to patient 
and family specific characteristics to identify CNV profiles that may be associated with ASD in 
subgroups of patients. The study sample contains 159 families ascertained through one or more 
clinically well characterized probands with non-syndromic ASD (55 multiplex, 104 simplex). In 
total 231 ASD patients (177 males, 54 females) and 99 siblings (34 males, 65 females) are 
included. The sample contains mainly patients with normal intelligence (89%). Genotyping for 
all family members was performed with lllumina Omni2.5-8v1 SNP array. After a statistical 
quality control, CNVs defined by less than 10 consecutive probes were excluded from the study. 
Thirteen variants with known clinical significance (CNV risk variants or causes of ASD) were also 
excluded. The remaining dataset consist of 21670 autosomal variants including 933 
homozygous deletions, 11746 deletions, 8926 duplications and 65 multiplications.  
 
Wilcoxon test statistics and 10000 permutation tests were used to compare de novo and 
inherited CNVs between ASD patients and unaffected siblings. The results show that ASD 
patients have significantly more de novo duplications than siblings (p < 0.04). In addition the 
gene content (average number of genes per de novo duplication) is higher in ASD patients (p < 
0.0006). Analyses in multiplex families revealed an overrepresentation of inherited duplications 
and a higher gene content in patients versus siblings (p < 0.003) while this was not present in 
simplex families. 
 
In conclusion, these family data support a role for duplications in the etiology of non-syndromic 
ASD. Further analysis and the relation with patient and family specific characteristics is subject 
of ongoing work. However a more distant aim is to unify our findings in existing family risk 
models and study the potential clinical significance. 
